Quantcast
Last updated on April 19, 2014 at 13:20 EDT

Latest osteosarcoma Stories

2012-10-17 15:23:55

-Immunocidin(TM) launched at Veterinary Cancer Society conference in Las Vegas, Nevada- BELLEVILLE, ON, Oct. 17, 2012 /PRNewswire/ - Bioniche Life Sciences Inc. (TSX: BNC) (ASX: BNC), a research-based, technology-driven Canadian biopharmaceutical company, today announced that its Immunocidin(TM) canine oncology therapy is being launched in North America at the annual Veterinary Cancer Society conference. The conference takes place from October 18th-21st in Las Vegas, Nevada....

2012-10-15 11:28:29

INDIANAPOLIS, Oct. 15, 2012 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today presented data comparing the effects of FORTEO and zoledronic acid on transiliac crest bone biopsies at six months in postmenopausal women with osteoporosis, based on additional analysis of data from the SHOTZ trial. Results, which were presented in an oral presentation at the 2012 Annual Meeting of the American Society for Bone and Mineral Research (ASBMR) in Minneapolis, MN, clearly differentiate the...

2012-09-08 23:02:34

Using a novel surgical approach, it´s possible to rebuild a functional lower jaw and mouth, and preserve a patient´s ability to eat and speak after removing an invasive facial tumor, according to a new report from Henry Ford Hospital in Detroit. Detroit, MI (PRWEB) September 07, 2012 Using a novel surgical approach, it´s possible to rebuild a functional lower jaw and mouth, and preserve a patient´s ability to eat and speak after removing an invasive facial tumor,...

2012-08-07 02:29:49

INDIANAPOLIS, Aug. 7, 2012 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced data from a Phase III trial comparing the effects of FORTEO(®) (teriparatide [rDNA origin] injection) and risedronate on back pain in postmenopausal women with osteoporotic vertebral fractures. The study showed no difference between FORTEO and risedronate on the primary endpoint of at least a 30 percent reduction in worst back pain from baseline to six months of therapy, as assessed by a numeric...

2012-07-23 10:25:25

-Canadian launch expected in September, 2012- BELLEVILLE, ON, July 23, 2012 /PRNewswire/ - Bioniche Life Sciences Inc. (TSX: BNC) (ASX: BNC), a research-based, technology-driven Canadian biopharmaceutical company, today announced that the first of two canine oncology products has received approval by regulators in both the U.S. and Canada. Market launch activities are currently underway with an expectation to have product available in September, 2012 in Canada, followed by a U.S....

2012-05-01 10:25:54

-one to launch as early as July of 2012- BELLEVILLE, ON, May 1, 2012 /PRNewswire/ - Bioniche Life Sciences Inc. (TSX: BNC) (ASX: BNC), a research-based, technology-driven Canadian biopharmaceutical company, today announced that it is commercializing two canine cancer products, one of which is expected to be launched in North America as early as July of this year. The Bioniche product that is nearest to market - Immunocidin(TM )- is based on the Company's proprietary mycobacterial...

2012-04-04 09:22:50

Many children with the bone cancer, osteosarcoma, die after the tumor spreads to their lungs. In a critical step toward finding a way to stop metastasis, researchers at Georgetown Lombardi Comprehensive Cancer Center say they have discovered an agent that prevents this type of cancer from spreading to the lungs in mice with the disease. The new agent stops or inhibits "ezrin," a protein vital to the spread of osteosarcoma, say the researchers who presented their findings today at the...

2011-11-21 18:02:00

NEW YORK, Nov. 21, 2011 /PRNewswire-USNewswire/ -- Current science indicates that water fluoridation is not only ineffective at reducing tooth decay, but is also harmful to health. Despite this knowledge, The Pew Charitable Trusts continues to promote fluoridation by using inaccurate information, and by lobbying legislators to conceal vital information on fluoride's adverse effects, reports The Fluoride Action Network (FAN). Pew Using Propaganda Instead of Science Pew has alleged that...

2011-09-19 19:15:00

SAN DIEGO, Sept. 19, 2011 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today presented a study that assessed the effects of 18 months of treatment with FORTEO(®) (teriparatide [rDNA origin] injection) on vertebral and proximal femoral strength, and the relationship of these effects to changes in the underlying volumetric BMD (vBMD) of postmenopausal women with osteoporosis. Researchers concluded that FORTEO increased vertebral and femoral strength in the spine and hip...

2011-09-19 19:00:00

SAN DIEGO, Sept. 19, 2011 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today presented data comparing the mechanisms of action of FORTEO® (teriparatide [rDNA origin] injection) and zoledronic acid based on data that evaluated histomorphometric measurements of bone remodeling in transiliac crest bone biopsies from postmenopausal women with osteoporosis. These data were presented in an oral presentation at the 2011 Annual Meeting of the American Society for Bone and...